A prospective, randomized multicenter, open-label, safety and preliminary efficacy study of Immunotherapy in patients with unresectable hepatocellular carcinoma (HCC) treated by transarterial chemoembolization (TACE)

Trial Profile

A prospective, randomized multicenter, open-label, safety and preliminary efficacy study of Immunotherapy in patients with unresectable hepatocellular carcinoma (HCC) treated by transarterial chemoembolization (TACE)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Sep 2016

At a glance

  • Drugs Dendritic cell vaccine-CreaGene (Primary) ; Cyclophosphamide
  • Indications Liver cancer
  • Focus Therapeutic Use
  • Acronyms IMMANUEL
  • Sponsors JW CreaGene
  • Most Recent Events

    • 16 Feb 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top